Sign in
Enrolling by invitationPhase 4

The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication

Key facts

Who runs it
National Cheng-Kung University Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
Phase
Phase 4
People taking part
312 people, planned
Started
6 May 2020
Expected to end
31 Jul 2028
Type of study
Interventional, 5 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Bismuth Subcitrate 120 MG Oral Tablet
  • Lactobacillus acidophilus and Bifidobacterium lactis Bb12
  • Esomeprazole 40mg
  • Metronidazole 250 MG
  • Tetracycline Pill
Record updated
24 June 2024

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Patients who are > 18 years
  • Receive gastroscopy because of dyspepsia, acid regurgitation, melena, hematemesis, or others

Who cannot take part

  • Diseases treated with chemotherapy within one month
  • Diseases treated with steroids within one month
  • Diseases treated with antibiotics within one month,
  • Users of aspirin within four weeks before enrollment
  • Users of nonsteroidal anti-inflammatory drugs within four weeks before enrollment
  • Users of cyclooxygenase-2 selective inhibitors within four weeks before enrollment
  • Ingest probiotics or probiotics-containing yogurt with a frequency of >= twice per week one month prior to enrollment
  • Bleeding diathesis,
  • Major organic diseases
  • Malignancy
  • History of H. pylori eradication

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Helicobacter pylori (H. pylori) infection is the major cause of gastritis, peptic ulcer disease, and gastric cancer in adults. Bismuth-based quadruple therapy is recommended by a recent review to be the first-line treatment for H. pylori eradication, replacing clarithromycin-based triple therapy. It is because the eradication rates of triple therapy in adults have declined due to increasing clarithromycin resistance. The best regimen for H. pylori eradication should be the one which succeeds on the first attempt. However, the effectiveness and the optimal duration of bismuth-based quadruple therapy for first-line H. pylori eradication in adults are unknown. Moreover, the impacts on gut microbiota after H. pylori eradication should be concerned; for example, bismuth-based quadruple therapy decreases F. prausnitzii richness. The transient perturbation of the gut microbiota after H. pylori eradication were restored at 8 weeks and one year in subjects receiving clarithromycin-based triple therapy but not fully recovered in those receiving bismuth-based quadruple therapy. Therefore, the important issues are that the short-term and long-term gut dysbiosis and the recovery of gut F. prausnitzii depletion in H. pylori-infected adult patients after bismuth-based quadruple therapy. It is also uncertain the role of irreversible gut dysbiosis even though H. pylori is eradicated in gastric persist inflammation and progress to cancer, and whether probiotics could be helpful in recovering gut dysbiosis.

Read full original descriptionShow less

The therapeutic strategy to eradicate H. pylori infection is based on antibiotics; however, this strategy not only increases drug resistant rates of the pathogen but also shapes the gut microbiota.

The investigators hypothesize that bismuth-based quadruple therapy could be an optimal regimen for first-line H. pylori eradication in the era of increasing clarithromycin resistance; moreover, gut dysbiosis could be reversed after bismuth-based quadruple therapy. Furthermore, the efficacy of the10-day course is not inferior to that of the 14-day course in H. pylori eradication. The investigators also hypothesize that probiotics could restore gastric or gut dysbiosis, especially gut F. prausnitzii depletion.

The 5 groups in the trial

  • The 14-day bismuth-based quadruple therapy groupExisting treatment, for comparison

    The patients receive a 14-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Flagyl 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.

    Treatment: Bismuth Subcitrate 120 MG Oral Tablet, Esomeprazole 40mg, Metronidazole 250 MG, and Tetracycline Pill

  • The 10-day bismuth-based quadruple therapy groupExisting treatment, for comparison

    The patients receive a 10-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Flagyl 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.

    Treatment: Bismuth Subcitrate 120 MG Oral Tablet, Esomeprazole 40mg, Metronidazole 250 MG, and Tetracycline Pill

  • The non-H. pylori-infected controlNo study treatment, for comparison

    Age- and sex-matched patients who do not have H. pylori infection by endoscopic gastric biopsy are enrolled as the non-H. pylori-infected control.

  • The probiotic therapy groupExisting treatment, for comparison

    The patients who still have depletion of gut F. prausnitzii 12 months after H. pylori eradication are enrolled into the probiotic supplement trial. They are randomized to the probiotic therapy group ingesting probiotic powder twice daily for 24 weeks. The probiotic powder is named as "President AB powder", which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of \>= 10E9 CFU/mL (President Corp., Tainan, Taiwan).

    Treatment: Lactobacillus acidophilus and Bifidobacterium lactis Bb12

  • The non-probiotic control groupNo study treatment, for comparison

    The patients who still have depletion of gut F. prausnitzii 12 months after H. pylori eradication are enrolled into the probiotic supplement trial. They are randomized to the non-probiotic control therapy and they do not ingest probiotic powder.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Studies of Integrating Gastric and Gut Microbiota, F. Prausnitzii Metabolites, Microenvironment, and Epigenetics to Identify the Cancer Risk of H. Pylori-related Precancerous Conditions Through an AI System and Control the Risky by Probiotic Supplements
Criteria questions
Built from NCT04527055, who can take part
Publications
Record updated
24 June 2024